Recent articles

  1. Study protocol

    Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma

    Marc-Andrea Baertsch, Jana Schlenzka, Elias K. Mai, Maximilian Merz, Jens Hillengaß, Marc S. Raab, Dirk Hose, Patrick Wuchter, Anthony D. Ho, Anna Jauch, Thomas Hielscher, Christina Kunz, Steffen Luntz, Stefan Klein, Ingo G. H. Schmidt-Wolf and Martin Goerner

    Published on: 25 April 2016

View all articles

Most accessed articles

Most Accessed Articles: BMC Cancerhttp://bmccancer.biomedcentral.comMost Accessed Articles: BMC CancerResveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression extracted from grape has been an ideal alternative drug in the therapy of different cancers including colorectal cancer (CRC). Since the underlying mechanisms of resveratrol on the invasion and met...Thu, 05 Mar 2015 00:00:00 GMT Ji, Xuan Liu, Zhifen Han, Lihong Zhou, Hua Sui, Linlin Yan, Haili Jiang, Jianlin Ren, Jianfeng Cai and Qi Li2015-03-05T00:00:00ZTime trends in municipal distribution patterns of cancer mortality in Spain disease mapping techniques widely used in small-area studies enable disease distribution patterns to be identified and have become extremely popular in the field of public health. This paper reports on tre...Thu, 24 Jul 2014 00:00:00 GMT López-Abente, Nuria Aragonés, Beatriz Pérez-Gómez, Marina Pollán, Javier García-Pérez, Rebeca Ramis and Pablo Fernández-Navarro2014-07-24T00:00:00ZLi-Fraumeni syndrome with simultaneous osteosarcoma and liver cancer: Increased expression of a CD44 variant isoform after chemotherapy syndrome (LFS) is a hereditary cancer predisposition syndrome that is commonly associated with a germline mutation in the tumor suppressor gene p53. Loss of p53 results in increased expression of CD44...Tue, 02 Oct 2012 00:00:00 GMT J Yoshida, Yasushi Fuchimoto, Tomoo Osumi, Hiroyuki Shimada, Seiichi Hosaka, Hideo Morioka, Makio Mukai, Yohei Masugi, Michiie Sakamoto and Tatsuo Kuroda2012-10-02T00:00:00ZExpression and role of oncogenic miRNA-224 in esophageal squamous cell carcinoma expression of miR-224 is associated with tumor development and progression. This study investigated the role of miR-224 in esophageal squamous cell carcinoma (ESCC) ex vivo and in vitro.Thu, 06 Aug 2015 00:00:00 GMT He, Zhimei Zhang, Ming Li, Shuo Li, Lihua Ren, Hong Zhu, Bin Xiao and Ruihua Shi2015-08-06T00:00:00ZE-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition is an adherens junction protein that forms homophilic intercellular contacts in epithelial cells while also interacting with the intracellular cytoskeletal networks. It has roles including establish...Wed, 30 Jul 2014 00:00:00 GMT Chen, Henry Beetham, Michael A Black, Rashmi Priya, Bryony J Telford, Joanne Guest, George A R Wiggins, Tanis D Godwin, Alpha S Yap and Parry J Guilford2014-07-30T00:00:00Z

View all articles


BMC Cancer publishes selected collections of research articles, conference proceedings, reviews and reports as supplements. While we build our new sites all supplements will be available here.

Aims and scope

BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.

Section Editors

  • Ian Cree, University Hospitals Coventry and Warwickshire
  • Manami Inoue, University of Tokyo
  • Ferdinando Mannello, University Carlo Bo of Urbino
  • Christophe Nicot, Kansas University Medical Center
  • Stephen P Povoski, The Ohio State University
  • Charles Rosser, University of Hawaii Cancer Center
  • Dirk Vordermark, Martin Luther University Halle-Wittenberg

Executive Editor

  • Dafne Solera, BioMed Central